Skip to menu Skip to content Skip to footer

2020

Journal Article

Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report

Dhanani, Jayesh, Pattison, David A., Burge, Matthew, Williams, Julian, Riedel, Bernhard, Hicks, Rodney J. and Reade, Michael C. (2020). Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 60, 319-322. doi: 10.1016/j.jcrc.2020.08.011

Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report

2020

Journal Article

The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT

Dudoignon, David, Pattison, David A., Legallois, Damien, Hicks, Rodney J. and Aide, Nicolas (2020). The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 20 (1) 68, 1-12. doi: 10.1186/s40644-020-00344-9

The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT

Featured

2020

Journal Article

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04944-2

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

2020

Journal Article

Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer

Violet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Sue-Ping Thang, , Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G., Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott G., Hicks, Rod J., Hofman, Michael S. and Tran, Ben (2020). Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61 (6), 857-865. doi: 10.2967/jnumed.119.236414

Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer

2020

Journal Article

Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer

Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S. P., Kong, G., Kumar, A. Ravi, Akhurst, T., Pattison, D. A., Beaulieu, A., Mooi, J., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J. and Hofman, M. S. (2020). Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer. Journal of Urology, 203 (5). doi: 10.1097/JU.0000000000000779.01

Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer

2019

Conference Publication

Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]

Sandhu, Shahneen, Tothill, Richard, Scolyer, Richard, Guminski, Alexander, Becker, Juergen, Poulsen, Michael, Atkinson, Victoria, Neeson, Paul, Shackleton, Mark, Pattison, David, Williams, Narelle and Paton, Elizabeth (2019). Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Hoboken, NJ, United States: Wiley.

Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]

2019

Conference Publication

A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer

Debowski, M., Gulhane, B., Ramsay, S. C., Thomas, P. A., Garcia, P., Latter, M., Tapper, S. and Pattison, D. A. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 49th ASM, Adelaide, SA, Australia, 26–28 April 2019. Hoboken, NJ, United States: Wiley.

A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer

2018

Conference Publication

Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)

Scott, Ashleigh P., Tey, Siok-Keen, Thomas, Paul, Pattison, David and Kennedy, Glen A. (2018). Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114114

Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)

2018

Journal Article

64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy

Hicks, Rodney J., Jackson, Price, Kong, Grace, Ware, Robert E., Hofman, Michael S., Pattison, David A., Akhurst, Timothy A., Drummond, Elizabeth, Roselt, Peter, Callahan, Jason, Price, Roger, Jeffery, Charmaine M., Hong, Emily, Noonan, Wayne, Herschtal, Alan, Hicks, Lauren J., Hedt, Amos, Harris, Matthew, Paterson, Brett M. and Donnelly, Paul S. (2018). 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 60 (6), 777-785. doi: 10.2967/jnumed.118.217745

64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy

2018

Conference Publication

(18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE

Robinson, B., Pattison, D. and Lee, K. (2018). (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE. HOBOKEN: WILEY.

(18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE

2018

Journal Article

Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging

Tang, Victor, Campbell, Patrina and Pattison, David A. (2018). Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging. Urology, 114, e1-e2. doi: 10.1016/j.urology.2017.12.010

Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging

2018

Journal Article

Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT

Bongetti, Elisa, Lee, Melissa H., Pattison, David A., Hicks, Rodney J., Norris, Richard, Sachithanandan, Nirupa and MacIsaac, Richard J. (2018). Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT. Clinical Case Reports, 6 (4), 719-722. doi: 10.1002/ccr3.1448

Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT

2018

Journal Article

Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors

Ladwa, Rahul, Wen Hong, Hooi, Wyld, David, Pattison, David A. and Burge, Matthew (2018). Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors. Clinical Nuclear Medicine, 43 (3), 186-187. doi: 10.1097/RLU.0000000000001970

Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors

2018

Conference Publication

Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors

2018

Conference Publication

Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT

Goodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018.

Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT

2018

Conference Publication

Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)

2018

Conference Publication

Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor

2018

Journal Article

Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging

Mossman, Anna K., Pattison, David A., Hicks, Rodney J., Hamblin, Peter S. and Yates, Christopher J. (2018). Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. Internal Medicine Journal, 48 (1), 97-98. doi: 10.1111/imj.13664

Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging

2018

Book Chapter

Management of distant metastasis in differentiated thyroid cancer

Pattison, David A., Miller, Julie A., Khavar, Bhadrakant and Tie, Jeanne (2018). Management of distant metastasis in differentiated thyroid cancer. Evidence-Based Endocrine Surgery. (pp. 121-140) Singapore: Springer Singapore. doi: 10.1007/978-981-10-1124-5_11

Management of distant metastasis in differentiated thyroid cancer

2017

Journal Article

Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma

Kong, Grace, Grozinsky-Glasberg, Simona, Hofman, Michael S., Callahan, Jason, Meirovitz, Amichay, Maimon, Ofra, Pattison, David A., Gross, David J. and Hicks, Rodney J. (2017). Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism, 102 (9), 3278-3287. doi: 10.1210/jc.2017-00816

Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma